← Back to all trials
Not Yet Recruiting
NCT05745857
Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas
Conditions: Barrett's Esophagus Without Dysplasia, Barrett Oesophagitis With Dysplasia, Esophageal Adenocarcinoma
Sex: All
Ages: 18 Years – N/A
Phase: PHASE2
Enrollment: 25
Sponsor: University Medical Center Groningen
Location: Netherlands
Summary
Previous studies have confirmed the great potential of quantitative fluorescence molecular endoscopy (qFME) when looking at additional lesion detection initially missed by high-definition white light endoscopy (HD-WLE) for surveillance of Barrett's esophagus.
Eligibility Criteria
Inclusion Criteria:BE patients without dysplasia and with suspected/diagnosed low-grade dysplasia (LGD), high-grade dysplasia (HGD) or superficial EAC and planned diagnostic and/or therapeutic endoscopyWritten informed consent is obtainedExclusion Criteria:Patients under the age of eighteen.Submucosal and invasive EAC, also defined as EAC with tumor, node and metastasis (TNM)-classification other than T1.Previous radiation therapy for esophageal cancerKnown immunoglobulin allergyPrevious chemotherapy, immunotherapy or related surgeryPrior bevacizumab or cetuximab treatmentMedical or psychiatric conditions that compromise the patient's ability to give informed consentPregnancy or breast feeding.
Source: ClinicalTrials.gov (NCT05745857). StuddyBuddy aggregates publicly available trial information.
